Table 4:
Risk factors for UTI and urosepsis during the initial Tx hospitalization in ADPKD patients.
| Univariable | Multivariable b | |||||||
|---|---|---|---|---|---|---|---|---|
| UTI or urosepsis during initial Tx hospitalization | Yes n = 14 | No n = 157 | RR a | 95%CI | P value | RR a | 95%CI | P value |
| Recipient age at Tx, mean ± SD (per 5 years) | 58.2 ± 8.8 | 54.9 ± 10.7 | 1.18 | 0.92; 1.51 | .198 | 1.10 | 0.71; 1.69 | .679 |
| Waiting time, mean ± SD (per 12 months) | 47.7 ± 37.3 | 43.4 ± 38.2 | 1.09 | 0.96; 1.23 | .180 | |||
| Female recipient, n (%) (yes vs no) | 6 (42.9) | 69 (44.0) | 0.87 | 0.32; 2.35 | .781 | |||
| Recipient diabetes mellitus, n (%) (yes vs no) | 3 (21.4) | 20 (12.9) | 1.77 | 0.54; 5.84 | .346 | |||
| Recipient BMI, mean ± SD (per 1 kg/m2) | 27.4 ± 3.3 | 25.9 ± 4.0 | 1.04 | 0.92; 1.17 | .501 | |||
| Recipient CCI score, mean ± SD (per 1 point) | 3.9 ± 1.0 | 3.5 ± 1.3 | 1.35 | 0.94; 1.93 | .104 | 1.13 | 0.59; 2.19 | .707 |
| Unilateral nephrectomy before Tx, n (%) (yes vs no) | 4 (28.6) | 57 (36.3) | 0.70 | 0.21; 2.34 | .564 | |||
| Donor age, mean ± SD (per 5 years) | 59.0 ± 11.2 | 54.8 ± 13.7 | 1.00 | 0.84; 1.20 | .966 | |||
| Donor eGFRcr, mean ± SD (per 5 ml/min/1.73 m2) | 80.0 ± 27.8 | 83.9 ± 24.0 | 1.01 | 0.92; 1.12 | .781 | |||
| Living donor, n (%) (yes vs no) | 3 (21.4) | 60 (38.2) | c | |||||
| Preemptive Tx, n (%) (yes vs no) | 2 (14.3) | 21 (13.4) | 0.92 | 0.20; 4.27 | .912 | |||
| AB0 compatible Tx, n (%) (yes vs no) | 12 (85.7) | 143 (91.1) | 0.70 | 0.14; 3.34 | .650 | |||
| Basiliximab, n (%) (yes vs no) | 13 (92.9) | 148 (94.3) | 0.92 | 0.11: 7.72 | .940 | |||
| Cyclosporine A, n (%) (yes vs no) | 3 (21.4) | 69 (44.0) | 0.23 | 0.06; 0.81 | .023 | |||
| Tacrolimus, n (%) (yes vs no) | 11 (78.6) | 84 (53.5) | 4.83 | 1.35; 17.28 | .015 | 6.44 | 1.66; 25.10 | .007 |
| Mycophenolate, n (%) (yes vs no) | 12 (85.7) | 147 (93.6) | 0.34 | 0.08; 1.34 | .121 | |||
| Rejection episode, n (%) (yes vs no) | 8 (57.1) | 32 (20.4) | 3.20 | 1.18; 8.71 | .023 | 5.24 | 1.68; 16.30 | .004 |
Immunosuppression refers to the initial treatment after transplantation. Patients were censored from the time at which both native kidneys had been removed. In 22 patients both native kidneys had been removed before transplantation. Steroids were not included because at this early stage after Tx all patients received steroids. Immunosuppression applied in <10 cases was excluded from the analysis to assure reliable risk estimates: belatacept, bortezomib, everolimus, fingolimod, plasmapheresis/intravenous immunoglobulins, rituximab, sotrastaurin, thymoglobulin.
Relative risk estimated by a generalized linear model by Poisson regression with robust error variance.
Multivariable model was identified by LASSO regression.
Parameter was not analyzed because of small population of cells in cross table.
Abbreviations: ADPKD, polycystic kidney disease; BMI, body mass index; CCI, Charlson Comorbidity Index; CI, confidence interval; eGFRcr, creatinine-based estimated glomerular filtration rate; SD, standard deviation; Tx, transplantation.